1. Home
  2. EBON vs INAB Comparison

EBON vs INAB Comparison

Compare EBON & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ebang International Holdings Inc.

EBON

Ebang International Holdings Inc.

HOLD

Current Price

$2.05

Market Cap

16.0M

Sector

Technology

ML Signal

HOLD

Logo IN8bio Inc.

INAB

IN8bio Inc.

HOLD

Current Price

$1.26

Market Cap

13.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EBON
INAB
Founded
2010
2016
Country
China
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
16.0M
13.7M
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
EBON
INAB
Price
$2.05
$1.26
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$6.00
AVG Volume (30 Days)
12.5K
40.1K
Earning Date
04-24-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.61
$1.17
52 Week High
$5.90
$2.73

Technical Indicators

Market Signals
Indicator
EBON
INAB
Relative Strength Index (RSI) 46.66 36.93
Support Level $1.74 $1.17
Resistance Level $2.84 $1.53
Average True Range (ATR) 0.15 0.08
MACD -0.01 -0.00
Stochastic Oscillator 12.82 4.89

Price Performance

Historical Comparison
EBON
INAB

About EBON Ebang International Holdings Inc.

Ebang International Holdings Inc is engaged in blockchain technology and fintech, with activities also extending to the solar industry, supported by its application-specific integrated circuit (ASIC) chip designs. The Company's business mainly includes the sale of bitcoin mining machines and related accessories, telecommunication products, solar and battery storage products, cryptocurrency exchange services, cross-border payment and foreign exchange services, SaaS data visualization and analytics solutions, and rental services. It generates the majority of its revenue from cross-border payment and foreign exchange services, with its operations mainly in mainland China and Australia, which contribute the maximum revenue.

About INAB IN8bio Inc.

IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.

Share on Social Networks: